✨ Your Portfolio is fetched and updated from zerodha.
Small
Market Cap
₹13,182 Cr.
P/E
30.28

Key Ratios

Market cap
Market cap
13,182 Cr
PE
PE
30.28
Prom Holding
Prom Holding
-
ROE (%)
ROE (%)
15.55
ROCE (%)
ROCE (%)
21.01
Div Yield (%)
Div Yield (%)
-
Sales
Sales
2,923 Cr
OPM (%)
OPM (%)
19.18 %
Debt to Equity
Debt to Equity
-
About
Indegene offers digital-led commercialization services to biopharmaceutical, emerging biotech,… Read more
Low
505
52W Range
High
705
  • Indegene
  • Syngene Internation.
  • Jubilant Pharmova

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

0 Yes

Positive for this company

0 Neutral

Neutral for this company

0 No

Negative for this company

0 No Data

Insufficient data to analyse

Peer Comparison
FAQs on Indegene Ltd. Business

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology.

Indegene major competitors are Syngene Internation., Jubilant Pharmova, Dr. Agarwal's Health, Granules India, Sanofi Cons. Health, Sanofi India, Alivus Life Sciences.
Market Cap of Indegene is ₹13,125 Crs.
While the median market cap of its peers are ₹12,500 Crs.

Indegene seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Jul Mar Jun Sep Dec
Investor Presentation Mar Apr Jul May Jun Sep Dec
Conference Call Mar Jun Mar Jun Sep Dec
Conference Call SummaryCon Call Summary
Discussions & Analysis
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material